Funder
Substance Abuse and Mental Health Services Administration
Subject
Psychiatry and Mental health,Clinical Psychology,Psychiatry and Mental health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Medicine (miscellaneous)
Reference32 articles.
1. Revisiting the X: BOT naltrexone clinical trial using a comprehensive survival analysis;Ajazi;Journal of Addiction Medicine,2022
2. A cluster-analytic profiling of heroin-dependent patients based on level, clinical adequacy, and patient-desired adjustment of buprenorphine dosage during buprenorphine-naloxone maintenance treatment in sixteen Spanish centers;Alcaraz;Drug and Alcohol Dependence,2018
3. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians;Arfken;Journal of Substance Abuse Treatment,2010
4. Aronowitz, Behrends, C. N., Lowenstein, M., Schackman, B. R., & Weiner, J. (2022, January 18). Lowering the Barriers to Medication Treatment for People with Opioid Use Disorder. Penn LDI. https://ldi.upenn.edu/our-work/research-updates/lowering-the-barriers-to-medication-treatment-for-people-with-opioid-use-disorder/.
5. Housing first for people with severe mental illness who are homeless: A review of the research and findings from the at Home—Chez soi demonstration project;Aubry;The Canadian Journal of Psychiatry,2015